Article Abstract

Revisiting anti-angiogenic therapy for recurrent glioblastoma

Authors: Katherine B. Peters

Abstract

Glioblastoma (GBM) represents the most common malignant primary brain neoplasm in adult patients with a median overall survival (OS) in a modern US population-based cancer registry data Surveillance, Epidemiology, and End Results (SEER) of 11 and 14.6 months based on standard of care therapy (1,2). Despite advances in treatment, GBM (WHO grade IV) is associated with considerable morbidity and mortality as compared with other malignancies.

Article Options

Download Citation